Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
2.
Neurologist ; 27(4): 183-193, 2022 Jul 01.
Article in English | MEDLINE | ID: mdl-35051970

ABSTRACT

BACKGROUND: Parkinson's disease (PD) is the second leading neurodegenerative disease worldwide. Important advances in monitoring and treatment have been made in recent years. This article reviews literature on utility of smartphone applications in monitoring PD symptoms that may ultimately facilitate improved patient care, and on movement modulation as a potential therapeutic. REVIEW SUMMARY: Novel mobile phone applications can provide one-time and/or continuous data to monitor PD motor symptoms in person or remotely, that may support precise therapeutic adjustments and management decisions. Apps have also been developed for medication management and treatment. CONCLUSIONS: Smartphone applications provide a wide array of platforms allowing for meaningful short-term and long-term data collection and are also being tested for intervention. However, the variability of the applications and the need to translate complicated sensor data may hinder immediate clinical applicability. Future studies should involve stake-holders early in the design process to promote usability and streamline the interface between patients, clinicians, and PD apps.


Subject(s)
Mobile Applications , Neurodegenerative Diseases , Parkinson Disease , Telemedicine , Humans , Parkinson Disease/diagnosis , Parkinson Disease/therapy , Smartphone
3.
J Neurol Sci ; 434: 120118, 2022 03 15.
Article in English | MEDLINE | ID: mdl-34971857

ABSTRACT

BACKGROUND AND AIMS: We highlight the peripheral neurologic complications of coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an ongoing global health emergency. METHODS: We evaluated twenty-five patients admitted to the COVID-19 Recovery Unit (CRU) at New York-Presbyterian Weill Cornell University Medical Center after intensive care hospitalization with confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), whom neurology was consulted for weakness and/or paresthesias. All patients were clinically evaluated by a neuromuscular neurologist who performed electrodiagnostic (EDX) studies when indicated. Magnetic resonance imaging (MRI) of the affected regions, along with nerve and muscle biopsies were obtained in select patients to better elucidate the underlying diagnosis. RESULTS: We found fourteen out of twenty-five patients with prolonged hospitalization for COVID-19 infection to have peripheral neurological complications, identified as plexopathies, peripheral neuropathies and entrapment neuropathies. The other eleven patients were not found to have peripheral neurologic causes for their symptoms. Patients with peripheral neurological complications often exhibited more than one type of concurrently. Specifically, there were four cases of plexopathies, nine cases of entrapment neuropathies, and six cases of peripheral neuropathies, which included cranial neuropathy, sciatic neuropathy, and multiple mononeuropathies. CONCLUSIONS: We explore the possibility that the idiopathic peripheral neurologic complications could be manifestations of the COVID-19 disease spectrum, possibly resulting from micro-thrombotic induced nerve ischemia.


Subject(s)
COVID-19 , Nervous System Diseases , Peripheral Nervous System Diseases , COVID-19/complications , Critical Care/methods , Humans , Nervous System Diseases/diagnostic imaging , Nervous System Diseases/etiology , Peripheral Nervous System Diseases/complications , Peripheral Nervous System Diseases/etiology , SARS-CoV-2
4.
Semin Neurol ; 41(6): 744-759, 2021 12.
Article in English | MEDLINE | ID: mdl-34826876

ABSTRACT

Neuropathic pain is a common chief complaint encountered by neurologists and primary care providers. It is caused by disorders involving the somatosensory nervous system. The clinical evaluation of neuropathic pain is challenging and requires a multifaceted systematic approach with an emphasis on a thorough history and physical examination to identify characteristic signs and symptoms. Ancillary laboratory investigations, targeted imaging, and electrodiagnostic studies further help identify underlying etiologies to guide specific treatments. Management of neuropathic pain encompasses treating the underlying pathology as well as symptomatic control with nonpharmacological, pharmacological, and interventional therapies. Here, we present an approach to help evaluate patients with neuropathic pain.


Subject(s)
Neuralgia , Humans , Neuralgia/diagnosis , Neuralgia/etiology , Neuralgia/therapy
6.
Clin Neurol Neurosurg ; 209: 106890, 2021 10.
Article in English | MEDLINE | ID: mdl-34455169

ABSTRACT

BACKGROUND AND OBJECTIVE: Levodopa off/on testing is frequently performed to assess medication response in patients with Parkinson's disease (PD) as an aid in determining best medical management or potential surgical candidacy. The Parkinson's Kinetigraph (PKG) is a wearable device which generates tremor, bradykinesia (BKS) and dyskinesia (DKS) scores representing motor symptoms over a six-day period. In this study, we compared off/on testing with PKG motor scores. METHODS: Patients were enrolled as part of an observational study: Assessing the Longitudinal Signs in PD, a three-year study evaluating clinical and biomarker evolution in patients with PD taking levodopa. Patients underwent off/on testing at baseline and 6-month visits. A greater than 30% improvement between off and on MDS-Unified Parkinson's Disease Rating Scale scores was considered a robust response. After each visit, patients wore the PKG for 6 days. A bradykinesia score (BKS) greater than 26 and dyskinesia score (DKS) greater than 9 were considered poorly controlled bradykinesia and dyskinesia, respectively. RESULTS: The median BKS at the baseline and 6-month visits were 27.15 and 27.55, respectively, despite a robust median off/on improvement at both visits. In addition, 10/18 (66%) and 7/13 (53.8%) patients with robust off/on improvement at the baseline and 6-month visits, respectively, demonstrated a BKS > 26 or DKS > 9. CONCLUSION: A robust off/on response during a clinic visit does not necessarily reflect adequately controlled motor symptoms. The PKG, by virtue of its continuous recording of motor movements, may provide additional clinically relevant data on motor symptoms which may be useful for prospective observational studies.


Subject(s)
Antiparkinson Agents/therapeutic use , Hypokinesia/drug therapy , Levodopa/therapeutic use , Parkinson Disease/drug therapy , Aged , Female , Humans , Hypokinesia/physiopathology , Male , Middle Aged , Parkinson Disease/physiopathology , Prospective Studies , Symptom Assessment , Treatment Outcome
7.
Case Rep Neurol Med ; 2021: 9925004, 2021.
Article in English | MEDLINE | ID: mdl-34194857

ABSTRACT

INTRODUCTION: Transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL) is defined as a secondary, nonvascular headache disorder characterized by the findings described in its name. Patients with HaNDL syndrome typically present with gradual onset migrainous headaches of moderate to severe intensity with transient neurological symptoms. Case Report. We discuss a patient who presented with thunderclap headache, recent transient neurologic deficits, and was ultimately diagnosed with HaNDL after an extensive neurologic evaluation. CONCLUSION: Thunderclap headache has very rarely been described in patients with HaNDL. After excluding emergent and secondary causes, HaNDL should be considered in patients with thunderclap-quality headaches, particularly when there is a history of transient neurological symptoms.

9.
J Clin Neuromuscul Dis ; 21(4): 225-229, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32453098

ABSTRACT

Bickerstaff brainstem encephalitis, widely considered to be associated with Miller Fisher and Guillain-Barré syndromes, is a rare disease state defined by the triad of ophthalmoplegia, ataxia, and decreased consciousness. The presence of central nervous system involvement, commonly in the form of impaired arousal, solidifies it as a unique entity. We present a case of this rare syndrome after autologous stem cell transplant.


Subject(s)
Encephalitis/diagnosis , Stem Cell Transplantation/adverse effects , Ataxia/complications , Brain Stem/pathology , Encephalitis/etiology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Ophthalmoplegia/complications , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/complications , Recurrence
10.
Neurologist ; 25(2): 26-27, 2020 Mar.
Article in English | MEDLINE | ID: mdl-32132496

ABSTRACT

INTRODUCTION: Intravenous thrombolytic therapy with recombinant tissue type plasminogen activator (IV-tPA) is the first-line treatment option for acute ischemic stroke (AIS). The tPA exclusion criteria, defined decades ago, require updates as new technologies emerge. Transcatheter aortic valve replacement (TAVR), which has begun to replace open surgery, poses a risk for acute stroke and falls outside of prior tPA guidelines. CASE REPORT: Here we describe a post-TAVR patient treated safely with IV-tPA for presumed AIS. CONCLUSION: Previously undescribed, we suggest that tPA should be considered for post-TAVR AIS patients who otherwise satisfy inclusion and exclusion criteria.


Subject(s)
Brain Ischemia/drug therapy , Stroke/surgery , Thrombolytic Therapy , Transcatheter Aortic Valve Replacement , Brain Ischemia/diagnosis , Brain Ischemia/surgery , Fibrinolytic Agents/therapeutic use , Humans , Stroke/etiology , Thrombolytic Therapy/adverse effects , Tissue Plasminogen Activator/therapeutic use
12.
Hum Brain Mapp ; 39(2): 1043-1055, 2018 02.
Article in English | MEDLINE | ID: mdl-29323797

ABSTRACT

Serotonin 1A (5-HT1A ) receptors play a direct role in neuronal development, cell proliferation, and dendritic branching. We hypothesized that variability in 5-HT1A binding can affect cortical thickness, and may account for a subtype of major depressive disorder (MDD) in which both are altered. To evaluate this, we measured cortical thickness from structural magnetic resonance imaging (MRI) and 5-HT1A binding by positron emission tomography (PET) in an exploratory study. To examine a range of 5-HT1A binding and cortical thickness values, we recruited 25 healthy controls and 19 patients with MDD. We hypothesized increased 5-HT1A binding in the raphe nucleus (RN) would be negatively associated with cortical thickness due to reduced serotonergic transmission. Contrary to our hypothesis, raphe 5-HT1A binding was positively correlated with cortical thickness in right posterior cingulate cortex (PCC), a region implicated in the default mode network. Cortical thickness was also positively correlated with 5-HT1A in each cortical region. We further hypothesized that the strength of 5-HT1A -cortical thickness correlation depends on the number of axons between the raphe nucleus and each region. To explore this we related 5-HT1A -cortical thickness correlation coefficients to the number of tracts connecting that region and the raphe, as measured by diffusion tensor imaging (DTI) in an independent sample. The 5-HT1A -cortical thickness association correlated significantly with the number of tracts to each region, supporting our hypothesis. We posit a defect in the raphe may affect the PCC within the default mode network in MDD through serotonergic fibers, resulting in increased ruminative processing.


Subject(s)
Brain/diagnostic imaging , Brain/metabolism , Depressive Disorder, Major/diagnostic imaging , Depressive Disorder, Major/metabolism , Receptor, Serotonin, 5-HT1A/metabolism , Adult , Brain/pathology , Carbon Radioisotopes , Diffusion Tensor Imaging , Female , Humans , Magnetic Resonance Imaging , Male , Multimodal Imaging , Neural Pathways/diagnostic imaging , Neural Pathways/metabolism , Neural Pathways/pathology , Organ Size , Piperazines , Positron-Emission Tomography , Pyridines , Radiopharmaceuticals
13.
Clin Pract ; 7(4): 1002, 2017 Sep 15.
Article in English | MEDLINE | ID: mdl-28959388

ABSTRACT

Cryptococcal meningoencephalitis is a leading of morbidity and mortality in immunocompromised individuals worldwide. However, there are few documented cases in immunocompetent patients. We present a rare case of disseminated Cryptococcus with progression to meningoencephalitis in an immunocompetent patient, with a possible atypical presentation. Magnetic resonance imaging of the brain and electroencephalogram to rule out brain metastasis were negative. Lumbar puncture resulted positive for Cryptococcus neoformans antigen at titers of 1:2048 and a detailed history later revealed occupational exposure to bird dander by cleaning floors and cages. Diagnosis is challenging, with delays often resulting in increased morbidity and mortality. Cerebrospinal fluid and serum Cryptococcus antigen play a key role in both diagnosis and determining treatment efficacy. Furthermore, current treatment guidelines are used for immunocompromised individuals. Due to the significant side effects of these medications, further research is needed to determine the optimal treatment duration for immunocompetent patients to minimize the need for unnecessary therapy.

SELECTION OF CITATIONS
SEARCH DETAIL
...